study,trt,class,n,r
allen 2017,placebo,placebo,126,54
allen 2017,desvenlafaxine standard,snri,131,33
allen 2017,desvenlafaxine high,snri,131,50
allen 2017,desvenlafaxine high,snri,132,58
allen 2017,desvenlafaxine high,snri,139,65
arnold 2010: 2,placebo,placebo,509,132
arnold 2010: 2,milnacipran standard,snri,516,216
arnold 2012: 2,placebo,placebo,275,80
arnold 2012: 2,esreboxetine standard,snri,264,110
arnold 2012: 2,esreboxetine standard,snri,272,116
arnold 2012: 2,esreboxetine high,snri,275,110
bateman 2011,milnacipran unable to be categorised,snri,79,26
bateman 2011,placebo,placebo,21,5
branco 2010,placebo,placebo,446,92
branco 2010,milnacipran high,snri,430,143
clauw 2008,placebo,placebo,401,100
clauw 2008,milnacipran standard,snri,399,149
clauw 2008,milnacipran high,snri,396,151
frakes 2011,placebo,placebo,260,70
frakes 2011,duloxetine high,snri,264,108
mease 2009,placebo,placebo,145,88
mease 2009,milnacipran standard,snri,128,97
mease 2009,milnacipran high,snri,239,186
murakami 2015,placebo,placebo,195,51
murakami 2015,duloxetine standard,snri,191,88
vollmer 2014,placebo,placebo,121,19
vollmer 2014,duloxetine standard,snri,118,29
vranken 2011,placebo,placebo,20,0
vranken 2011,duloxetine high,snri,23,5
wang 2017,placebo,placebo,177,36
wang 2017,duloxetine standard,snri,172,67